FDMT logo

FDMT

Profile

Full Name

4D Molecular Therapeutics, Inc.

Ticker Symbol

FDMT

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

December 11, 2020

Indexes

Not included

Website

http://www.4dmoleculartherapeutics.com

Employees

227

Key Details

Price

$2.94(+5.94%)

Market cap

$136.36M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$37.00K(-99.82% YoY)

Annual EPS

-$2.98(-15.50% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$2.94
FDMT price is $2.94

30-Day Relative Volume

1.15
FDMT 30-day relative volume is 1.15

Price Performance

Price Today change

+5.94%
FDMT price is up +5.94% today

Price YTD change

-47.13%
FDMT price is down -47.13% since January 1st

Price 1-year change

-88.78%
FDMT price is down -88.78% year-on-year

Price 3-year change

-77.72%
FDMT price is down -77.72% over the past 3 years

Price Range

Price All-time high

$55.11
FDMT price is currently -94.66% below its historical high of $55.11

Price 3-year low

$2.23
FDMT price is currently +31.77% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$136.36M
FDMT market capitalization is $136.36 million

Market cap 3-year change

-68.03%
FDMT market capitalization is down -68.03% over the past 3 years

Market cap All-time high

$1.83B
FDMT market capitalization is currently -92.54% below its historical high of $1.83 billion

Market cap sector rank

52.38%
FDMT market capitalization is higher than 52.38% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-9.49%
FDMT shares outstanding is down -9.49% year-on-year

Shares Outstanding 3-Year Change

+43.51%
FDMT shares outstanding is up +43.51% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.16
FDMT beta is 1.16

200-day SMA

$9.58
FDMT price is currently -69.27% below its 200-day simple moving average

50-day SMA

$4.13
FDMT price is currently -28.64% below its 50-day simple moving average

RSI

36.22
FDMT 14-day relative strength index is 36.22

Volume

1.15
FDMT 30-day relative volume is 1.15

ATR

$0.30
FDMT average true range is $0.30

10-day Historical Volatility

119.92%
FDMT 10-day historical volatility is 119.92%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$37.00K
FDMT annual revenue is $37.00 thousand

Revenue Analysts estimate

$4.85M
FDMT annual revenue is currently -99.24% lower than the consensus analysts' forecast

Revenue 1-year change

-99.82%
FDMT annual revenue is down -99.82% year-on-year

Revenue Sector rank

3.7%
FDMT annual revenue is higher than 3.7% of companies in Healthcare sector

EPS

EPS

-$2.98
FDMT annual earnings per share is -$2.98

EPS Analysts estimate

-$3.57
FDMT annual earnings per share is currently -16.51% lower than the consensus analysts' forecast

EPS 1-year change

-15.5%
FDMT annual earnings per share is down -15.5% year-on-year

EPS Sector rank

29.94%
FDMT annual earnings per share is higher than 29.94% of companies in Healthcare sector

Profit

Gross profit

-
FDMT annual gross profit value is unknown

Gross margin

-
FDMT annual gross profit margin value is unknown

Operating profit

-$187.84M
FDMT annual operating income is -$187.84 million

Operating margin

-507.68K%
FDMT annual operating profit margin is -507.68 thousand%

Net income

-$160.87M
FDMT annual net profit is -$160.87 million

Net margin

-434.78K%
FDMT annual net profit margin is -434.78 thousand%

Expenses

Total expenses

$187.88M
FDMT annual total expenses is $187.88 million

Operating expenses

$187.88M
FDMT annual total operating expenses is $187.88 million

Cost of goods sold

-
FDMT annual cost of goods sold value is unknown

Selling, general & administrative expenses

$46.58M
FDMT annual SGA is $46.58 million

Depreciation and amortization

$6.71M
FDMT annual depreciation & amortization is $6.71 million

Interest expense

-
FDMT annual interest expense value is unknown

Income tax

-
FDMT annual income tax value is unknown

EBIT & EBITDA

EBIT

-$187.84M
FDMT annual earnings before interest & taxes is -$187.84 million

EBITDA

-$181.14M
FDMT annual EBITDA is -$181.14 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$560.38M
FDMT annual total assets is $560.38 million

Non current assets

$125.45M
FDMT annual long term assets is $125.45 million

Current assets

$434.93M
FDMT annual total current assets is $434.93 million

Cash and cash equivalents

$149.34M
FDMT annual cash & cash equivalents is $149.34 million

Accounts receivable

-
FDMT annual accounts receivable value is unknown

Inventory

-
FDMT annual inventory value is unknown

Liabilities

Total liabilities

$49.78M
FDMT annual total liabilities is $49.78 million

Long term liabilities

$20.63M
FDMT annual total long term liabilities is $20.63 million

Current liabilities

$29.15M
FDMT annual total current liabilities is $29.15 million

Accounts payable

$4.39M
FDMT annual accounts payable is $4.39 million

Debt

Total debt

$24.61M
FDMT annual total debt is $24.61 million

Total debt 1-year change

+67.72%
FDMT annual total debt is up +67.72% year-on-year

Long term debt

$18.97M
FDMT annual long term debt is $18.97 million

Short term debt

$5.64M
FDMT annual short term debt is $5.64 million

Equity & Capital

Shareholders equity

$510.61M
FDMT annual stockholders equity is $510.61 million

Book value

$510.61M
FDMT annual book value is $510.61 million

Retained earnings

-$576.20M
FDMT annual retained earnings is -$576.20 million

Working capital

$405.78M
FDMT annual working capital is $405.78 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$134.59M
FDMT annual cash flow from operations is -$134.59 million

Cash from operations 1-year change

-77.57%
FDMT annual cash flow from operations is down -77.57% year-on-year

Cash from investing

-$302.44M
FDMT annual cash flow from investing activities is -$302.44 million

Cash from investing 1-year change

-361.36%
FDMT annual cash flow from investing activities is down -361.36% year-on-year

Cash from financing

$337.25M
FDMT annual cash flow from financing activities is $337.25 million

Cash from financing 1-year change

+115.04%
FDMT annual cash flow from financing activities is up +115.04% year-on-year

CAPEX

CAPEX

$3.79M
FDMT annual capital expenditures is $3.79 million

CAPEX 1-year change

+36.63%
FDMT annual capital expenditures is up +36.63% year-on-year

Free Cash Flow

Free cash flow

-$138.37M
FDMT annual free cash flow is -$138.37 million

Free cash flow 1-year change

-76.13%
FDMT annual free cash flow is down -76.13% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
FDMT annual gross profit margin value is unknown

Operating margin

-507.68K%
FDMT annual operating profit margin is -507.68 thousand%

Net margin

-434.78K%
FDMT annual net profit margin is -434.78 thousand%

ROA & ROE

ROA

-35.74%
FDMT annual return on assets is -35.74%

ROE

-39.31%
FDMT annual return on equity is -39.31%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
FDMT price to earnings ratio value is unknown

PE ratio Sector rank

-
FDMT price to earnings ratio is unknown

PB Ratio

PB ratio

0.27
FDMT price to book ratio is 0.27

PB ratio Sector rank

21.98%
FDMT price to book ratio is higher than 21.98% of companies in Healthcare sector

PS Ratio

PS ratio

3685.42
FDMT price to sales ratio is 3685.42

PS ratio Sector rank

99.74%
FDMT price to sales ratio is higher than 99.74% of companies in Healthcare sector

Enterprise value

Enterprise value

$11.63M
FDMT enterprise value is $11.63 million

Enterprise value Sector rank

26.28%
FDMT enterprise value is higher than 26.28% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.06
FDMT EV/EBITDA is -0.06

EV/EBITDA Sector rank

63.3%
FDMT EV/EBITDA is higher than 63.3% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

14.92
FDMT annual current ratio is 14.92

Quick ratio

-
FDMT annual quick ratio value is unknown

Leverage

Debt to equity

0.00
FDMT annual debt to equity ratio is 0.00

Interest coverage ratio

-
FDMT annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
FDMT piotroski f-score value is unknown

Altman Z-Score

-0.03
FDMT altman z-score is -0.03

Analyst ratings

Recent major analysts updates

Mar 10, 25 B of A Securities
Buy
Mar 4, 25 Chardan Capital
Buy
Mar 3, 25 RBC Capital
Outperform
Mar 3, 25 HC Wainwright & Co.
Buy
Feb 11, 25 Chardan Capital
Buy
Feb 10, 25 HC Wainwright & Co.
Buy
Jan 13, 25 Morgan Stanley
Underweight
Jan 13, 25 Leerink Partners
Outperform
Jan 13, 25 HC Wainwright & Co.
Buy
Dec 18, 24 B of A Securities
Buy

Institutional Ownership

Similar stocks

Kalaris Therapeutics (KLRS)
SLN logo
Silence Therapeutics (SLN)
SCPH logo
scPharmaceuticals (SCPH)
ACRS logo
Aclaris Therapeutics (ACRS)
ALDX logo
Aldeyra Therapeutics (ALDX)
RGLS logo
Regulus Therapeutics (RGLS)
OGI logo
OrganiGram Holdings (OGI)
LYEL logo
Lyell Immunopharma (LYEL)
SERA logo
Sera Prognostics (SERA)
  • What is the ticker symbol for 4D Molecular Therapeutics?
  • Does 4D Molecular Therapeutics pay dividends?
  • What sector is 4D Molecular Therapeutics in?
  • What industry is 4D Molecular Therapeutics in?
  • What country is 4D Molecular Therapeutics based in?
  • When did 4D Molecular Therapeutics go public?
  • Is 4D Molecular Therapeutics in the S&P 500?
  • Is 4D Molecular Therapeutics in the NASDAQ 100?
  • Is 4D Molecular Therapeutics in the Dow Jones?
  • When was 4D Molecular Therapeutics's last earnings report?
  • When does 4D Molecular Therapeutics report earnings?
  • Should I buy 4D Molecular Therapeutics stock now?

What is the ticker symbol for 4D Molecular Therapeutics?

The ticker symbol for 4D Molecular Therapeutics is NASDAQ:FDMT

Does 4D Molecular Therapeutics pay dividends?

No, 4D Molecular Therapeutics does not pay dividends

What sector is 4D Molecular Therapeutics in?

4D Molecular Therapeutics is in the Healthcare sector

What industry is 4D Molecular Therapeutics in?

4D Molecular Therapeutics is in the Biotechnology industry

What country is 4D Molecular Therapeutics based in?

4D Molecular Therapeutics is headquartered in United States

When did 4D Molecular Therapeutics go public?

4D Molecular Therapeutics's initial public offering (IPO) was on December 11, 2020

Is 4D Molecular Therapeutics in the S&P 500?

No, 4D Molecular Therapeutics is not included in the S&P 500 index

Is 4D Molecular Therapeutics in the NASDAQ 100?

No, 4D Molecular Therapeutics is not included in the NASDAQ 100 index

Is 4D Molecular Therapeutics in the Dow Jones?

No, 4D Molecular Therapeutics is not included in the Dow Jones index

When was 4D Molecular Therapeutics's last earnings report?

4D Molecular Therapeutics's most recent earnings report was on Feb 28, 2025

When does 4D Molecular Therapeutics report earnings?

The next expected earnings date for 4D Molecular Therapeutics is May 9, 2025

Should I buy 4D Molecular Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page